DK2085470T3 - FVII- eller FVIIa-varianter - Google Patents

FVII- eller FVIIa-varianter

Info

Publication number
DK2085470T3
DK2085470T3 DK09075170.2T DK09075170T DK2085470T3 DK 2085470 T3 DK2085470 T3 DK 2085470T3 DK 09075170 T DK09075170 T DK 09075170T DK 2085470 T3 DK2085470 T3 DK 2085470T3
Authority
DK
Denmark
Prior art keywords
fvii
variants
fviia variants
rhfviia
hfviia
Prior art date
Application number
DK09075170.2T
Other languages
English (en)
Inventor
Mads Roepke
Jesper Mortensen Haaning
Steven Glazer
Kim Vilbour Andersen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK2085470T3 publication Critical patent/DK2085470T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09075170.2T 2003-03-20 2004-03-22 FVII- eller FVIIa-varianter DK2085470T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45654703P 2003-03-20 2003-03-20
US47970803P 2003-06-19 2003-06-19
EP04722232A EP1608745B1 (en) 2003-03-20 2004-03-22 FVII OR FVIIa VARIANTS

Publications (1)

Publication Number Publication Date
DK2085470T3 true DK2085470T3 (da) 2012-08-06

Family

ID=33032721

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09075170.2T DK2085470T3 (da) 2003-03-20 2004-03-22 FVII- eller FVIIa-varianter
DK04722232T DK1608745T3 (da) 2003-03-20 2004-03-22 FVII eller FVIIa-Varianter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04722232T DK1608745T3 (da) 2003-03-20 2004-03-22 FVII eller FVIIa-Varianter

Country Status (10)

Country Link
US (2) US7771996B2 (da)
EP (2) EP1608745B1 (da)
JP (2) JP4847856B2 (da)
AT (1) ATE431403T1 (da)
AU (2) AU2004221761B2 (da)
CA (1) CA2519873C (da)
DE (1) DE602004021099D1 (da)
DK (2) DK2085470T3 (da)
ES (2) ES2386010T3 (da)
WO (1) WO2004083361A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第VII因子または第VIIa因子様分子
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
ATE431403T1 (de) 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
CA2529828C (en) * 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
CA2592521A1 (en) 2004-08-17 2006-02-23 Csl Behring Gmbh Modified vitamin k dependent polypeptides
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
WO2007026021A1 (en) 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Hydrophobic interaction chromatography purification of factor vii polypeptides
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
EP2004214B1 (en) 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Local treatment with factor vii
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
AU2013204377B2 (en) * 2007-04-13 2015-07-16 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
EP2147096B1 (en) 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子vii多肽和其用途
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX2015007712A (es) * 2012-12-24 2015-09-07 Bayer Healthcare Llc Polipeptidos del factor vii de accion corta.
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746A (fi) 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインc及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634T4 (de) 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE69131292T2 (de) 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
ES2109336T3 (es) * 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種pivkaの測定方法および測定試薬
CA2162726A1 (en) 1993-05-21 1994-12-08 Kathleen L. Berkner Modified factor vii
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
ES2265159T3 (es) * 1996-11-08 2007-02-01 Oklahoma Medical Research Foundation Uso de una proteina c modificada.
AU735187C (en) * 1997-01-22 2002-04-18 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして/又は除去された付着基を有するポリペプチド−ポリマー結合体
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
WO2001082943A2 (en) * 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
WO2000026230A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Low allergenic protein variants
DE69939548D1 (de) 1998-11-06 2008-10-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第VII因子または第VIIa因子様分子
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第vii凝固因子変異型
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ES2429523T3 (es) * 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
AU2001287550B2 (en) * 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
WO2002029084A2 (en) 2000-10-02 2002-04-11 Novo Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
RU2338752C2 (ru) 2001-03-22 2008-11-20 Ново Нордиск Хелт Кэр Аг Производные фактора vii свертывания крови
AU2002333211B2 (en) 2001-09-27 2008-05-08 Novo Nordisk Health Care Ag Human coagulation factor VII polypeptides
ES2490590T3 (es) 2001-11-02 2014-09-04 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación humana
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
NZ536340A (en) 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
ATE431403T1 (de) 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
CA2529828C (en) 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins

Also Published As

Publication number Publication date
DE602004021099D1 (de) 2009-06-25
AU2004221761A1 (en) 2004-09-30
US7771996B2 (en) 2010-08-10
CA2519873A1 (en) 2004-09-30
WO2004083361A3 (en) 2004-11-04
JP4847856B2 (ja) 2011-12-28
DK1608745T3 (da) 2009-06-15
US20070054366A1 (en) 2007-03-08
US20100330669A1 (en) 2010-12-30
JP2006521098A (ja) 2006-09-21
ATE431403T1 (de) 2009-05-15
EP1608745B1 (en) 2009-05-13
AU2004221761B2 (en) 2010-01-07
ES2386010T3 (es) 2012-08-07
EP2085470A1 (en) 2009-08-05
EP1608745A2 (en) 2005-12-28
WO2004083361A2 (en) 2004-09-30
EP2085470B1 (en) 2012-05-16
JP2012095641A (ja) 2012-05-24
ES2327044T3 (es) 2009-10-23
CA2519873C (en) 2012-12-18
AU2010201201A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
DK2085470T3 (da) FVII- eller FVIIa-varianter
DK1263941T3 (da) Xylanasevarianter med ændret sensitivitet overfor xylanaseinhibitorer
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
ATE462006T1 (de) Isoform des vegfs
IS2552B (is) Hindrar á Þátt Xa og aðra serín próteasa sem tengjast storknunarkeðjuverkun
DK1549677T3 (da) FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
NO20063624L (no) FC region varianter
CY1109614T1 (el) Μορια παρομοια με παραγοντα vii ή viia
DE60332774D1 (de) Verbesserte sso7-polymerase-konjugat-proteine
CY1111626T1 (el) ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
HUP0401658A2 (hu) Humán szöveti faktor ellenanyagok
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
TR199902751T2 (xx) Proteaz inhibit�rleri.
ATE515248T1 (de) Dentalzusammensetzung mit einem enzym
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
DE602006011069D1 (de) Trennscheibe
DK2284251T3 (da) Alkalisk protease med forøget specifik aktivitet over for casein
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
WO2004110469A3 (en) Formulations comprising factor viia and a factor vii related polypeptide
DK0833848T3 (da) Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
ATE375360T1 (de) Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
FI972605A (fi) Vähentyneen korrodoivan vaikutuksen omaava muurahaishappoliuos
ATE374260T1 (de) Asthma-assoziiertes gen